ARCHIVES

Genentech Move Nixes Hospital Discounts: Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker

This article is from The Cancer Letter archive.

Vol. 40 No. 37 | October 3, 2014

Download PDF Visit The Full Archive

Related Articles

In Senate testimony, NCI director uses survival rate as measure of progress for goal to “eliminate suffering and death due to cancer.”

July 29, 2005

NCCR Calls For 15% Increase In NIH Budget, “Investment Priority”

February 11, 1994

Brain tumor foundations form collaboration.

July 15, 2005

Ibrutinib Increases OS, PFS Versus Ofatumumab in Phase III

June 27, 2014

Roswell Park Wins Competition for Organ Systems Coordinating Center

May 18, 1984

NIH Probing: Double Dipping” Allegation

September 4, 1981